286 related articles for article (PubMed ID: 34587481)
21. Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19.
Satyam A; Tsokos MG; Brook OR; Hecht JL; Moulton VR; Tsokos GC
Clin Immunol; 2021 May; 226():108716. PubMed ID: 33774179
[TBL] [Abstract][Full Text] [Related]
22. Immune response to COVID-19 infection: a double-edged sword.
Saad N; Moussa S
Immunol Med; 2021 Sep; 44(3):187-196. PubMed ID: 33444511
[TBL] [Abstract][Full Text] [Related]
23. Systems serology detects functionally distinct coronavirus antibody features in children and elderly.
Selva KJ; van de Sandt CE; Lemke MM; Lee CY; Shoffner SK; Chua BY; Davis SK; Nguyen THO; Rowntree LC; Hensen L; Koutsakos M; Wong CY; Mordant F; Jackson DC; Flanagan KL; Crowe J; Tosif S; Neeland MR; Sutton P; Licciardi PV; Crawford NW; Cheng AC; Doolan DL; Amanat F; Krammer F; Chappell K; Modhiran N; Watterson D; Young P; Lee WS; Wines BD; Mark Hogarth P; Esterbauer R; Kelly HG; Tan HX; Juno JA; Wheatley AK; Kent SJ; Arnold KB; Kedzierska K; Chung AW
Nat Commun; 2021 Apr; 12(1):2037. PubMed ID: 33795692
[TBL] [Abstract][Full Text] [Related]
24. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.
Lipcsey M; Persson B; Eriksson O; Blom AM; Fromell K; Hultström M; Huber-Lang M; Ekdahl KN; Frithiof R; Nilsson B
Front Immunol; 2021; 12():627579. PubMed ID: 33692801
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
26. Complement Activation in Kidneys of Patients With COVID-19.
Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
Front Immunol; 2020; 11():594849. PubMed ID: 33584662
[TBL] [Abstract][Full Text] [Related]
27. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
[TBL] [Abstract][Full Text] [Related]
28. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Müller E; Rampini SK; Boyman O
J Allergy Clin Immunol; 2021 Feb; 147(2):545-557.e9. PubMed ID: 33221383
[TBL] [Abstract][Full Text] [Related]
29. The Systemic Immune Response in COVID-19 Is Associated with a Shift to Formyl-Peptide Unresponsive Eosinophils.
Koenderman L; Siemers MJ; van Aalst C; Bongers SH; Spijkerman R; Bindels BJJ; Giustarini G; van Goor HMR; Kaasjager KAH; Vrisekoop N
Cells; 2021 May; 10(5):. PubMed ID: 34062964
[TBL] [Abstract][Full Text] [Related]
30. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
[TBL] [Abstract][Full Text] [Related]
32. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
Koutsakos M; Rowntree LC; Hensen L; Chua BY; van de Sandt CE; Habel JR; Zhang W; Jia X; Kedzierski L; Ashhurst TM; Putri GH; Marsh-Wakefield F; Read MN; Edwards DN; Clemens EB; Wong CY; Mordant FL; Juno JA; Amanat F; Audsley J; Holmes NE; Gordon CL; Smibert OC; Trubiano JA; Hughes CM; Catton M; Denholm JT; Tong SYC; Doolan DL; Kotsimbos TC; Jackson DC; Krammer F; Godfrey DI; Chung AW; King NJC; Lewin SR; Wheatley AK; Kent SJ; Subbarao K; McMahon J; Thevarajan I; Nguyen THO; Cheng AC; Kedzierska K
Cell Rep Med; 2021 Mar; 2(3):100208. PubMed ID: 33564749
[TBL] [Abstract][Full Text] [Related]
33. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
Front Immunol; 2021; 12():684014. PubMed ID: 34194438
[TBL] [Abstract][Full Text] [Related]
34. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
[TBL] [Abstract][Full Text] [Related]
35. Immune profiling of COVID-19: preliminary findings and implications for the pandemic.
Maecker HT
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963016
[TBL] [Abstract][Full Text] [Related]
36. Complement(ing) long-COVID thromboinflammation and pathogenesis.
Lee JD; Woodruff TM
Trends Immunol; 2024 Jun; 45(6):397-399. PubMed ID: 38637200
[TBL] [Abstract][Full Text] [Related]
37. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
[TBL] [Abstract][Full Text] [Related]
39. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
40. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients.
Cheng L; Zhang X; Chen Y; Wang D; Zhang D; Yan S; Wang H; Xiao M; Liang T; Li H; Xu M; Hou X; Dai J; Wu X; Li M; Lu M; Wu D; Tian R; Zhao J; Zhang Y; Cao W; Wang J; Yan X; Zhou X; Liu Z; Xu Y; He F; Li Y; Yu X; Zhang S
Signal Transduct Target Ther; 2021 Aug; 6(1):304. PubMed ID: 34404759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
